A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women

Osteoporosis Clinical Trial

Official title:

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Absolute Bioavailability, Pharmacokinetics, and Pharmacodynamics of AGA2118 in Men and Postmenopausal Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05225857
• Other study ID #: 21-001
• Status: Completed
• Phase: Phase 1
• Start date: June 28, 2022
• Est. completion date: January 13, 2024

Study information

• Verified date: February 2023
• Source: Angitia Biopharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of the study are to assess the safety and tolerability of AGA2118 after single subcutaneous or intravenous administration in healthy men and postmenopausal women and to assess the safety and tolerability of AGA2118 after multiple subcutaneous administrations in men and postmenopausal women.

Description:

This is a Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Absolute Bioavailability, Pharmacokinetics, and Pharmacodynamics of AGA2118 in Men and Postmenopausal Women.

The study consists of the single ascending dose (SAD) part and the multiple ascending dose (MAD) part. In the SAD part, up to 56 healthy men and postmenopausal women will be sequentially enrolled to receive a single subcutaneous (SC) dose of AGA2118 or a single intravenous (IV) dose of AGA2118 or placebo. In the MAD part, up to 32 healthy men and postmenopausal women will be sequentially enrolled in various dose cohorts to receive multiple SC doses every 4 weeks of AGA2118 or placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: January 13, 2024
• Est. primary completion date: January 13, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Healthy men = 30 and = 65 years of age or postmenopausal women = 45 and = 65 years of age for SAD and MAD;

2. BMI = 18.5 and = 32 kg/m^2 (for SAD and MAD).

3. Generally healthy (as assessed by the investigator).

4. Nonsmokers, or light smokers, defined as = 3 cigarettes/day (or equivalent) (for SAD and MAD).

5. Able and willing to correctly and independently complete all study procedures and able to read, understand, and provide written informed consent after the nature of the study has been fully explained and must be willing to comply with all study requirements and procedures (for SAD and MAD).

6. A male who is sterile or agrees to the following during the Treatment Period and for at least 6 months after the final dose of investigational product

• Refrain from donating fresh unwashed semen

Plus, either

• Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent

OR

• Must agree to use contraception as detailed below

• Agree to use a male condom plus a female partner to use a highly effective method of contraception with a woman of childbearing potential who is not currently pregnant

• Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person

Exclusion Criteria:

1. A bone fracture within 6 months (for SAD only).

2. Previous exposure to AGA2118 (for MAD only).

3. Any condition that would affect bone metabolism or has a history of low energy fractures as documented in medical history (for MAD only).

4. Administration of the any medications that known to affect bone metabolism within 6 months of Day 1 unless otherwise specified (for SAD and MAD).

5. Human immunodeficiency virus (HIV) infection (for SAD and MAD).

6. Active chronic hepatitis B (HBV) or hepatitis C (HCV) infection including hepatitis B surface antigen and hepatitis C antigen positive participants with or without abnormal liver enzymes (for SAD and MAD).

7. Evidence of any of the following (for SAD and MAD):

1. creatinine = 1.5 × ULN, or estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m^2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula at screening

2. current hyper- or hypocalcemia, defined as albumin-adjusted serum calcium outside the normal range

3. known intolerance to calcium supplements

4. malignancy within the last 5 years, etc.

Related Conditions & MeSH terms

• Osteoporosis

Intervention

Drug:
• AGA2118
Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV. Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC.
• Placebo
Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV. Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC.

Locations

Country	Name	City	State
Australia	Q-Pharm Pty Ltd	Brisbane	Queensland
Australia	Nucleus Network Pty Ltd.	Melbourne	Victoria

Sponsors (2)

Lead Sponsor	Collaborator
Angitia Biopharmaceuticals	Angitia Australia Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-emergent adverse events (TEAE) in Part 1 (SAD).	An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP.	Up to 85 days
Primary	Number of participants with clinically significant changes in total calcium (albumin-adjusted) in Part 1 (SAD).	Serum calcium tested at Day 2, 4, 6, 15, 29, 85.	Up to 85 days
Primary	Number of participants with clinically significant changes in blood pressure in Part 1 (SAD).	Systolic and diastolic blood pressure measured (mmHg) at all clinic visits (Day 1, 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85).	Up to 85 days
Primary	Number of participants with clinically significant changes in heart rate in Part 1 (SAD).	Heart rate measured by electrocardiogram (ECG) on Day 1, 2, 4, 6, 15, 29, 85.	Up to 85 days
Primary	Number of participants with clinically significant changes in QTcF in Part 1 (SAD).	QTcF (QT interval corrected for heart rate using Fridericia's formula) measured by electrocardiogram (ECG) on Day 1, 2, 4, 6, 15, 29, 43, 57, 71, 85.	Up to 85 days
Primary	Number of participants with treatment-emergent adverse events (TEAE) in Part 2 (MAD).	An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP.	Up to 169 days
Primary	Number of participants with clinically significant changes in total calcium (albumin-adjusted) in Part 2 (MAD).	Serum calcium tested at Day 2, 8, 15, 29, 36, 57, 64, 85, 169.	Up to 169 days
Primary	Number of participants with clinically significant changes in blood pressure in Part 2 (MAD).	Systolic and diastolic blood pressure measured (mmHg) at all clinic visits (Day 1, 2, 4, 6, 8, 15, 22, 29, 36, 43, 57, 58, 60, 62, 64, 71, 78, 85, 99, 113, 127, 141, 155, 169).	Up to 169 days
Primary	Number of participants with clinically significant changes in heart rate in Part 2 (MAD).	Heart rate measured by electrocardiogram (ECG) on Day 1, 2, 4, 15, 29, 36, 57, 64, 85, 169.	Up to day 169
Primary	Number of participants with clinically significant changes in QTcF in Part 2 (MAD).	QTcF (QT interval corrected for heart rate using Fridericia's formula) measured by electrocardiogram (ECG) on Day 1, 2, 4, 15, 29, 36, 57, 64, 85, 169.	Up to day 169
Secondary	Maximum Concentration (Cmax) of AGA2118	Maximum concentration of AGA2118 after dosing.	Part 1 (SAD): up to day 85; Part 2 (MAD) up to day 169
Secondary	Time to maximum concentration (Tmax) of AGA2118	Time to maximum concentration of AGA2118 after dosing.	Part 1 (SAD): up to day 85; Part 2 (MAD) up to day 169
Secondary	Area under the concentration time curve (AUC)	Definite integral of the curve describing the variation of AGA2118 in blood as a function of time.	Part 1 (SAD): up to day 85; Part 2 (MAD) up to day 169
Secondary	Terminal elimination half-life (t1/2)	Time it takes for maximum concentration to half of maximum concentration of AGA2118.	Part 1 (SAD): up to day 85; Part 2 (MAD) up to day 169